Dexmedetomidine Relieves Neuropathic Pain in Rats With Chronic Constriction Injury via the Keap1–Nrf2 Pathway

Yatao Liu, Wei Liu, Xiaoqing Wang, Zhan-Hai Wan, Yongqiang Liu, Mengjie ZhangFrontiers in Cell and Developmental Biology 2021 · DOI

TL;DR

This study reveals that dexmedetomidine (Dex) alleviates neuropathic pain in rats by activating the Keap1-Nrf2 pathway, which in turn reduces inflammation, apoptosis, and oxidative stress in the spinal cord. This work provides a novel mechanistic insight into Dex's analgesic effects and highlights the Keap1-Nrf2 pathway as a potential therapeutic target for neuropathic pain.

What Problem Does This Paper Address?

Neuropathic pain (NP) is a chronic pain condition resulting from damage to the somatosensory system, characterized by complex mechanisms and often insufficient treatment outcomes. While spinal cord neuronal dysfunction is implicated, current treatments are limited. Previous research has pointed to the roles of reactive oxygen species (ROS), inflammation, and central nervous system injury in NP pathogenesis. Dexmedetomidine (Dex), a well-known sedative and analgesic, has shown promise in alleviating NP through various signaling pathways. However, the specific molecular mechanisms by which Dex exerts its analgesic effects in the context of chronic constriction injury (CCI)-induced NP, particularly concerning the Keap1-Nrf2 pathway, remained largely unexplored. This paper aims to fill this gap by investigating Dex's role in modulating the Keap1-Nrf2 pathway and its downstream effects on inflammation, apoptosis, and redox balance in CCI-induced NP.

Methods

The researchers employed a multi-faceted approach to investigate the role of Dex and the Keap1-Nrf2 pathway in CCI-induced neuropathic pain in a rat model.

  • Neuropathic Pain Model: A chronic constriction injury (CCI) model was established in rats by ligating the sciatic nerve.
  • Behavioral Assessment: Neuropathic pain severity was quantified using paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) tests, which measure mechanical allodynia and thermal hyperalgesia, respectively.
  • Molecular Analysis:
    • Immunohistochemistry: Used to visualize the expression levels of Keap1 and Nrf2 in spinal cord tissues.
  • Quantitative Polymerase Chain Reaction (qPCR): Employed to measure the mRNA levels of various genes, including antioxidant genes (CAT, GPX1, GPX4, SOD1, SOD2, GCLC, GCLM, HMOX1, NQO1), pro-apoptotic factors (caspase-9, Bax, Bak), and key pathway molecules (Keap1, Nrf2, HO-1).
  • Western Blotting (WB): Used to determine the protein expression levels of Keap1, Nrf2, HO-1, and apoptotic markers.
  • Enzyme-Linked Immunosorbent Assay (ELISA): Utilized to quantify the release of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).
  • Antioxidant Assays: Measured glutathione (GSH) content, catalase (CAT) activity, and superoxide dismutase (SOD) activity.
  • Luciferase Reporter Assay: Assessed the activity of the antioxidant response element (ARE) to evaluate Nrf2 transcriptional activity.
  • Genetic Manipulation: To elucidate the specific role of the Keap1-Nrf2 pathway, lentiviral vectors were used to either upregulate (overexpress) or downregulate (silence) Keap1 expression in the spinal cord.

Datasets

Not discussed in the paper. The study primarily utilizes experimental data generated from animal models and in vitro assays.

Key Insights and Ideas

  • Dexmedetomidine's Dual Action: Dex not only alleviates the behavioral symptoms of neuropathic pain (reduced allodynia and hyperalgesia) but also tackles the underlying pathological processes by repressing inflammation, apoptosis, and redox disorders in the spinal cord.
  • Keap1-Nrf2 Pathway as the Mediator: The study strongly implicates the Keap1-Nrf2 pathway as the central mechanism through which Dex exerts its analgesic effects. Dex appears to "unlock" this pathway, which is normally suppressed in neuropathic pain.
  • Keap1 as a Gatekeeper: Keap1 acts as a negative regulator of Nrf2. In the context of CCI-induced NP, Keap1 expression is upregulated, leading to decreased Nrf2 activity. Dex treatment reverses this, downregulating Keap1 and consequently upregulating Nrf2.
  • Nrf2's Protective Role: Activated Nrf2, in turn, upregulates downstream antioxidant genes (like HO-1) and promotes cellular defense mechanisms, counteracting the oxidative stress associated with NP.
  • Inflammation and Apoptosis Link: The findings suggest a strong correlation between the Keap1-Nrf2 pathway and the regulation of inflammation and apoptosis. Activating Nrf2 (by downregulating Keap1) reduces pro-inflammatory cytokines and apoptotic markers.
  • Therapeutic Potential of Keap1 Modulation: The study demonstrates that manipulating Keap1 levels can directly impact neuropathic pain. Overexpressing Keap1 exacerbates NP, while silencing Keap1 mimics the beneficial effects of Dex, highlighting Keap1 as a promising therapeutic target.

Key Results

  • Dex Alleviates Pain Behavior: Dex treatment significantly increased PWT and PWL in CCI rats, indicating reduced mechanical allodynia and thermal hyperalgesia.
  • Dex Reduces Inflammation and Apoptosis: Dex treatment substantially decreased the expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and apoptotic markers (caspase-9, Bax, Bak) in the spinal cord of CCI rats.
  • Dex Activates Keap1-Nrf2 Pathway: Dex administration led to a significant downregulation of Keap1 expression and a significant upregulation of Nrf2 and its downstream target HO-1 in the spinal cord. This was further supported by increased ARE luciferase activity, indicating enhanced Nrf2 transcriptional activity.
  • Keap1 Overexpression Counteracts Dex: Overexpressing Keap1 in Dex-treated CCI rats reversed the analgesic effects of Dex, leading to increased PWT and PWL, and also aggravated inflammation and apoptosis.
  • Keap1 Silencing Mimics Dex: Silencing Keap1 in CCI rats significantly alleviated NP, increased PWT and PWL, and reduced inflammation and apoptosis, similar to the effects of Dex treatment.
  • Antioxidant Gene Upregulation: Dex treatment restored the expression and activity of antioxidant genes and enzymes (CAT, GPX1, SOD, GSH) that were downregulated in CCI rats. Keap1 overexpression reversed these beneficial effects, while Keap1 silencing promoted them.

Limitations and Future Work

  • Translational Potential: While the study demonstrates promising results in a rat model, further research is needed to confirm these findings in other animal models and to explore the translational potential of Dex or Keap1-targeting therapies for human neuropathic pain.
  • Specificity of Dex Action: Although the study focuses on the Keap1-Nrf2 pathway, Dex has other known pharmacological actions. Future work could further delineate the precise contribution of the Keap1-Nrf2 pathway relative to other potential mechanisms of Dex.
  • Long-term Effects: The study primarily focuses on short-to-medium term effects. Investigating the long-term efficacy and safety of Dex or Keap1 modulation in chronic pain conditions would be valuable.
  • Clinical Translation: The authors suggest that Dex plays a role in maintaining redox homeostasis by regulating Keap1 levels in CCI rats. This highlights the potential for therapeutic interventions targeting this pathway for neuropathic pain management. Further clinical studies are warranted to explore this possibility.

Summary updated

Abstract

This study aimed to determine the role of dexmedetomidine (Dex) in neuropathic pain (NP) after chronic constriction injury (CCI) in a rat model as well as its underlying mechanism. First, a CCI rat model was established. After treatment with Dex, the severity of NP was ascertained by monitoring paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) at different time points. Immunohistochemical analysis was performed to determine the levels of Keap1 and Nrf2 in the spinal cord. Furthermore, the levels of Keap1-Nrf2-HO-1 pathway molecules, apoptotic proteins, and antioxidant genes in the spinal cord or isolated primary microglia were determined using quantitative polymerase chain reaction and western blotting. The release of proinflammatory cytokines was detected via enzyme-linked immunosorbent assay. To evaluate Dex-treated CCI-induced NP via the Keap1-Nrf2-HO-1 pathway, the rats were intrathecally injected with lentivirus to upregulate or downregulate the expression of Keap1. We found that Dex inhibited pathological changes and alleviated sciatic nerve pain as well as repressed inflammation, apoptosis, and redox disorders of the spinal cord in CCI rats. Keap1 protein expression was substantially downregulated, whereas Nrf2 and HO-1 expressions were significantly upregulated in the spinal cord after Dex administration. Additionally, Keap1 overexpression counteracted Dex-mediated inhibition of NP. Keap1 overexpression led to a decrease in Nrf2 and HO-1 levels as well as PWT and PWL but led to an aggravation of inflammation and antioxidant disorders and increased apoptosis. Keap1 silencing alleviated NP in rats with CCI, as evidenced by an increase in PWT and PWL. Keap1 depletion resulted in the alleviation of inflammation and spinal cord tissue injury in CCI rats. Collectively, these findings suggest that Dex inhibits the Keap1-Nrf2-HO-1-related antioxidant response, inflammation, and apoptosis, thereby alleviating NP in CCI rats.
BibTeX
@inproceedings{liu2021dexmedetomidine,
  author = {Yatao Liu and Wei Liu and Xiaoqing Wang and Zhan-Hai Wan and Yongqiang Liu and Mengjie Zhang and Yong-Qiang Liu and Meng-Jie Zhang},
  title = {{Dexmedetomidine Relieves Neuropathic Pain in Rats With Chronic Constriction Injury via the Keap1–Nrf2 Pathway}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.714996},
}
Figure